← All indications
Mucopolysaccharidosis I
A group of autosomal recessive lysosomal storage disorders caused by mutations in the gene encoding the enzyme, alpha-L-iduronidase (IDUA), required for the degradation of heparan and dermatan sulfates. This leads to abnormal accumulation of these glycosaminoglycans in various tissues causing a wide range of clinical presentations including cognitive and musculoskeletal disorders.
Drugs by status
Approved for this indication (1)
Phase 3 trials (4)
Phase 2 trials (15)
Phase 1 trials (4)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (7)
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (9)
- Biomarin
- Bellicum Pharmaceuticals
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute of Neurological Disorders and Stroke (NINDS)
- UCLA Medical Center
- University of California, San Francisco
- National Center for Advancing Translational Science (NCATS)
- The University of Texas, Dallas